Literature DB >> 9349995

Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.

T Sato1, J Kato, J Kawanishi, K Kogawa, M Ohya, S Sakamaki, Y Niitsu.   

Abstract

A 43-year-old Japanese man who was positive for hepatitis B surface (HBs) antigen and HB e antibody, underwent chemotherapy for non-Hodgkin's lymphoma. After the chemotherapy he suffered from acute exacerbation of hepatitis because of reactivation of HBV. Recovery was achieved with interferon-alpha, glucagon-insulin therapy, and plasma exchange. Mutations were detected in codons 97, 100, 129, and 131 of the core region of HBV. The peptide encoded from the core region including such mutations possibly had greater antigenicity to induce cytotoxic T cell activity in the host. Core region mutations may be a crucial cause of the acute exacerbation of hepatitis B seen after chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349995     DOI: 10.1007/bf02934119

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  13 in total

1.  Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy.

Authors:  L T Soh; P T Ang; I Sng; E J Chua; Y W Ong
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

2.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

3.  Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection.

Authors:  T Ehata; M Omata; O Yokosuka; K Hosoda; M Ohto
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

4.  Recurrent fulminant hepatic failure in an HB carrier after intensive chemotherapy.

Authors:  M Yoshiba; K Sekiyama; S Iwabuchi; M Takatori; Y Tanaka; T Uchikoshi; H Okamoto; K Inoue; F Sugata
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

5.  Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

Authors:  R M Galbraith; A L Eddleston; R Williams; A J Zuckerman
Journal:  Lancet       Date:  1975-09-20       Impact factor: 79.321

6.  Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B.

Authors:  P C Pinto; E Hu; M Bernstein-Singer; L Pinter-Brown; S Govindarajan
Journal:  Cancer       Date:  1990-02-15       Impact factor: 6.860

7.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

8.  Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients.

Authors:  J Y Lau; C L Lai; H J Lin; A S Lok; R H Liang; P C Wu; T K Chan; D Todd
Journal:  Q J Med       Date:  1989-10

9.  Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen.

Authors:  H Okamoto; S Yotsumoto; Y Akahane; T Yamanaka; Y Miyazaki; Y Sugai; F Tsuda; T Tanaka; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

10.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.

Authors:  A Sette; A Vitiello; B Reherman; P Fowler; R Nayersina; W M Kast; C J Melief; C Oseroff; L Yuan; J Ruppert; J Sidney; M F del Guercio; S Southwood; R T Kubo; R W Chesnut; H M Grey; F V Chisari
Journal:  J Immunol       Date:  1994-12-15       Impact factor: 5.422

View more
  5 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Optimizing antiviral agents for hepatitis B management in malignant lymphomas.

Authors:  Oluwatobi O Ozoya; Julio Chavez; Lubomir Sokol; Samir Dalia
Journal:  Ann Transl Med       Date:  2017-02

3.  A fatal case of acute hepatitis B developed in a toluene abuser.

Authors:  Hideaki Kato; Jun Monma-Ohtaki; Makoto Nakamura; Yuji Nishi; Makoto Ohyama; Yoshitaka Maeno; Yoshimi Seko-Nakamura; Saeko Nagao; Masataka Nagao
Journal:  Clin J Gastroenterol       Date:  2008-05-16

4.  Hepatitis B virus reactivation in a patient undergoing steroid-free chemotherapy.

Authors:  Daisuke Shimizu; Kenichi Nomura; Yosuke Matsumoto; Kyoji Ueda; Kanji Yamaguchi; Masahito Minami; Yoshito Itoh; Shigeo Horiike; Masuji Morita; Masafumi Taniwaki; Takeshi Okanoue
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

5.  Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal study.

Authors:  Meng-Shen Dai; Pei-Fen Wu; Jang-Jih Lu; Rong-Yaun Shyu; Tsu-Yi Chao
Journal:  Support Care Cancer       Date:  2004-03       Impact factor: 3.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.